


EPILEPSY & SEIZURES

The Clinical Cognitive Aid: Diagnosis,
Pharmacotherapy, and Emergency Workflows



Austrroads 2022
Aligned




ILAE 2017
Classification



Med2Date 2026
Guidelines

The Clinical Workflow



Step 1: Evaluating the First Seizure Presentation

Provoked (Acute Symptomatic)

Timing: Within 7 days of acute insult.

Causes: Hypoglycaemia, hyponatraemia, alcohol withdrawal, stroke.

Recurrence Risk: Low (<10%) if corrected.

Driving: Minimum 4 weeks.

Unprovoked

Timing: No acute precipitant.

Causes: Genetic, structural, cryptogenic.

Recurrence Risk: 40–50% at 2 years.

Driving: Minimum 6 months.



Metabolic Red Flag Panel - Mandatory Exclusions

Blood glucose (<3.0 mmol/L) | Sodium (<120 mmol/L) | Calcium | Magnesium | Renal/Hepatic function | Toxicology

Step 2: Acute Neuroimaging & MRI Protocols

CT Head (Non-Contrast)



When: Acutely in ED (Available 24/7, MBS Item 56001).

Indications: Focal neurological signs, persistent altered consciousness, anticoagulation, suspected structural lesion/haemorrhage.

Limitation: Poor sensitivity for cortical dysplasia or hippocampal sclerosis.

MRI Brain (Epilepsy Protocol)



When: First-line for ALL unprovoked seizures (MBS Item 63060/63063).

Protocol Detail: Must include thin coronal T2/FLAIR sequences through the temporal lobes and hippocampi.

Logistics: Requires neurology/neurosurgery referral; potential 4–8 week wait in regional Australia. Paediatrics may require general anaesthesia.

Step 3: EEG Timing & The Diagnostic Threshold



EEG Logistics & Timing

Perform within 24–48 hours to maximize sensitivity (~50–70%).

Routine EEG:
20–30 mins
(MBS Item 11005).

Sleep-Deprived EEG: 3–4 hours sleep prior; improves yield if routine is normal.


Step 4: Austroads 2022 Driving Restrictions & Mandatory Notification



Mandatory Notification: Doctors have a legal obligation to notify the relevant driver licensing authority (e.g., VicRoads, Transport NSW) when a patient experiences a seizure. Patients must be counselled not to drive.


Seizure Type	Private License	Commercial License
Single Provoked:	🕒 Min 4 weeks	🕒 Min 6 months
Single Unprovoked:	🕒 Min 6 months 🚗	🚗 Min 12 months + specialist review 🧑🏻⚕️
Established Epilepsy (≥2 unprovoked):	Min 12 months seizure-free 🚗	Generally disqualifying
Sleep-Only Seizures:	3 years exclusively nocturnal	Disqualifying

The Seizure Classification Tree (ILAE 2017)



Clinical Clue: Focal aware seizures (auras) maintain consciousness and may be mistaken for anxiety or migraines.

Recognizing Common Epilepsy Syndromes



The 6-Year-Old

(Childhood Absence)

Multiple daily 5-30s staring spells.
Normal cognition.
EEG: 3 Hz spike-and-wave.

First-line: Ethosuximide or Valproate.

Prognosis: 60-70% remit by adolescence.



The 15-Year-Old

(Juvenile Myoclonic - JME)

Morning myoclonic jerks, generalised tonic-clonic, photosensitivity.

First-line: Valproate (males) / Levetiracetam (females).

Prognosis: Lifelong ASM needed; >90% controlled.



The 8-Year-Old

(BECTS / Rolandic)

Nocturnal hemifacial/oropharyngeal focal seizures.
Centrotemporal spikes.

First-line: Often none needed, or Carbamazepine.

Prognosis: Remits by age 15.



The Young Adult

(Temporal Lobe - TLE)

Focal impaired awareness, automatisms, epigastric rising aura.
MRI: Hippocampal sclerosis.

First-line: Carbamazepine, Lamotrigine.

Prognosis: 60-70% responsive; surgical candidate if refractory.

Secondary Causes & Specialist Referral Triggers



New **focal neurological deficit**



Progressive **headache / Papilloedema**



Fever with neck stiffness
(Meningitis/Encephalitis)



History of **malignancy**
(Metastases)



Immunosuppression
(Abscess, PML, CNS lymphoma)



'Thunderclap' headache (SAH)
or new onset
age >40.

Neurology Referral Checklist

(MBS Item 104/99)

- All new diagnoses
- Suspected PNES
(accounts for 20-30% of clinic referrals)
- Women of childbearing age
- Refractory Epilepsy
(defined as failure of ≥ 2 appropriate, adequately dosed ASMs)

The Master ASM Selection Grid

Seizure Type	First-Line	Second-Line	AVOID
Focal:	Levetiracetam, Carbamazepine, Lamotrigine	Clobazam, Topiramate	Valproate in childbearing women
Generalised Tonic-Clonic:	Valproate, Levetiracetam	Lamotrigine, Topiramate	Carbamazepine, Phenytoin - may worsen
Absence:	Ethosuximide, Valproate	Lamotrigine	Carbamazepine, Phenytoin, Gabapentin
Myoclonic (JME):	Valproate for males, Levetiracetam	Clobazam	Carbamazepine, Phenytoin, Pregabalin - exacerbates myoclonus

Key Principle: Start low, go slow. Monotherapy to lowest effective dose. Never abruptly cease ASMs.

Broad-Spectrum Monotherapy Profiles



Levetiracetam (Keppra®)

Broadest first-line spectrum.

Dose:

Start 250 mg PO BD → Target
500-1500 mg BD.

Metabolism:

Minimal hepatic metabolism.
NO CYP450 interactions (Major advantage).
Renal adjustment required (eGFR <80).

Adverse:

Behavioural/psychiatric (irritability,
aggression 5-15%), somnolence.




Lamotrigine (Lamictal®)

Preferred in pregnancy.

Dose:

SLOW titration mandatory. Start 25 mg PO
OD for 2 weeks → target 100-200 mg BD.

Adverse:

 Serious rash (SJS/TEN) risk highest
with rapid titration or valproate
co-administration.

Pregnancy: Lowest teratogenic risk.
Clearance increases 50-100% by 3rd
trimester (requires dose increase).

Targeted Monotherapy Profiles

Carbamazepine (Tegretol®)

Sodium channel blocker for Focal seizures.

Dose:

Start 100 mg PO BD with food → Target 200-800 mg BD.

Interactions:

Potent CYP3A4 inducer. Massively interacts with oral contraceptives and DOACs.

Pharmacogenomics:

HLA-B*1502 testing recommended before initiation in SE Asian/Indian ancestry (SJS risk).

Adverse:

Diplopia, ataxia, hyponatraemia (SIADH).

Ethosuximide (Zarontin®)

Strictly for Absence seizures.

Dose:



Start 500 mg PO OD → Target 750-1500 mg/day.

Adverse:

GI upset, drowsiness.

Note: Equal efficacy to valproate for absence but fewer adverse effects.

Sodium Valproate & The Teratogenicity Danger Zone

  Sodium Valproate (Epilim®)

Broadest efficacy, highest danger.

Dose: Target trough 50-100 mg/L.

Adverse: Weight gain, tremor, hair loss, rare hepatotoxicity. Avoid in severe hepatic impairment.

The Teratogenicity Danger Zone

5-10%

Risk of Major Congenital Malformations (Neural tube defects, cardiac).

30-40%

Risk of Neurodevelopmental Disorders (Autism spectrum, 7-10 point IQ reduction).

Mandatory Protocol: TGA Pregnancy Prevention Programme: Women of childbearing potential MUST be enrolled. Requires annual review, documented pregnancy tests, and highly effective contraception.

Emergency Management: Pre-Hospital & Early ED (0-5 Min)

0 MIN

Seizure Begins



First Aid Checkmarks:

- ✓ Position on side.
- ✓ Protect head.
- ✓ Time the seizure.
- ✗ Do NOT restrain.
- ✗ Do NOT insert anything in mouth.

5 MIN


First-Line Benzodiazepines (Pre-Hospital)

If no IV access:

-  **Midazolam 10 mg IM** (preferred pre-hospital)
- OR **Diazepam 10-20 mg PR.** 

5 MIN

ED Arrival & Initial Assessment

 **ABCs**, establish IV access, continuous pulse oximetry.

Check BGL Immediately:

If **<3.0 mmol/L**, give **50 mL of 50% glucose (25 g)** IV bolus.
Give **Thiamine 100 mg** IV first if alcohol misuse suspected.

Status Epilepticus Escalation Timeline



Convulsive Status Epilepticus: ≥ 5 mins of continuous seizure OR ≥ 2 discrete seizures without recovery.
15-20% adult mortality if untreated > 30 mins.

05 MIN


IV Benzodiazepines

Diazepam 10 mg IV
(over 2-3 mins, repeat once at 5 min)
OR
Lorazepam 4 mg IV.




20 MIN

Second-Line ASMs

Seizure persists. 
Give **ONE**:
IV Levetiracetam 60 mg/kg
(max 4500 mg, safest profile)
OR
IV Sodium Valproate 40 mg/kg
(max 3000 mg, avoid in women)
OR
IV Fosphenytoin 20 mg PE/kg
(needs cardiac monitoring).

40 MIN

Refractory Status (ICU)

Rapid Sequence Intubation (RSI) + 
continuous EEG.

Continuous IV infusion:
Midazolam, Propofol, or Thiopentone.

Contraception & ASM Interaction Matrix

A

Enzyme-Inducing ASMs

(Carbamazepine, Phenytoin, Topiramate >200mg, Oxcarbazepine).



Effect:

Reduces efficacy of combined pill (COC), progestogen-only pill, implants, and depot.



Action:

Use Levonorgestrel IUD (Mirena®) or Copper IUD. If using COC, requires $\geq 50 \mu\text{g}$ ethinyloestradiol with continuous use.



B

Non-Inducing ASMs

(Levetiracetam, Valproate, Ethosuximide)



Effect:

No significant interaction. Standard contraceptive options apply.




Standard contraceptive options apply.



C


The Lamotrigine Exception

(Bidirectional interaction)



Effect:

COC reduces Lamotrigine levels by ~50% (**risk of breakthrough seizures**). Monitor levels closely.



Pregnancy Planning & The Catamenial Cycle

Pre-Conception Checklist

- ✓ Folic acid **5 mg** daily (high dose) started **≥1 month** before conception. Standard **0.5 mg** is inadequate.
- ✓ Switch away from Valproate **≥3 months** prior.
- ✓ Establish baseline ASM levels (especially Lamotrigine/Levetiracetam, which require **50-100%** dose increases by 3rd trimester).

The Catamenial Cycle Overlay

Danger Zone 1
(Catamenial Type 1)


Perimenstrual drop
in progesterone

Danger Zone 2
(Catamenial Type 2)

Periovulatory
estrogen surge

Danger Zone 1
(Catamenial Type 1)

Perimenstrual drop
in progesterone



! **Intervention:** Clobazam 10-20mg luteal-phase rescue or hormonal IUD.

Considerations for Special Populations



Paediatrics

Simple febrile seizures (<15 min) need no ASM.

Suspect Dravet Syndrome (*SCN1A*) if prolonged infant seizures → strictly **AVOID** sodium channel blockers (*Carbamazepine*, *Lamotrigine*) as they exacerbate seizures.



The Elderly (≥65 yrs)

Highest incidence demographic. Presentations often subtle (confusion, falls).

AVOID Phenytoin/Phenobarbitone (falls/cognitive impairment) and **Carbamazepine** (hyponatraemia).

Preferred:
Levetiracetam/Lamotrigine

Assess bone health (DEXA) if on enzyme inducers.



Immunocompromised

HIV/Chemo/Transplant.
High suspicion for CNS infections/lymphoma.

Preferred ASM: *Levetiracetam* or *Lacosamide* (no interaction with tacrolimus/ARVs).

Avoid enzyme inducers which cause transplant rejection.

Pharmacokinetic Adjustments: Renal & Hepatic Impairment



Renal Impairment

Levetiracetam

⚠ Requires strict dose reduction.

eGFR 50–80 (Max 1000mg BD); eGFR <30 (250–500mg BD). Add supplemental dose post-dialysis.

Gabapentin/Pregabalin

⚠ Significant dose reduction required by eGFR.

Valproate/Lamotrigine/Carbamazepine

● No dose adjustment generally required.



Hepatic Impairment

Valproate

⚠ **CONTRAINDICATED** in severe hepatic impairment.

Monitor LFTs at 1, 3, 6, and 12 months.

Carbamazepine/Phenytoin/Lamotrigine


⚠ Metabolized hepatically; use with extreme caution, reduce doses, monitor free drug levels.

Levetiracetam

● Preferred choice (minimal hepatic metabolism).


Aboriginal & Torres Strait Islander Epilepsy Care

Epidemiology Bar Chart/Stat




Prevalence is 1.5–2x higher, with disproportionately elevated status epilepticus and mortality rates, often linked to TBI and CNS infections.

Care Integration Model



Synthesis: Treating the Patient, Not Just the Seizure



Insight Callout

Optimal care is a delicate balancing act. A structurally perfect drug for a seizure (e.g., Valproate for JME) can be a catastrophic choice for the patient's demographic (a woman of childbearing age). Mastery requires synthesizing all variables simultaneously.